Pricing Log in Create free account
Friday 6 November 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

LGND Healthcare Biotechnology

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue
−31.8%
EPS
−123.9%
Free cash flow
−268.5%
Total debt
+52.6%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%
Market cap
$6.0B
P/E
116×
Fwd P/E
88.3×
Dividend yield
—
F-score
6/9
Altman Z
5.45
Beneish M
−4.02
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Ligand Pharmaceuticals Incorporated (LGND) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a EV/Sales of 24.7×. Over the past ten years it has ranged from 2.6× (September 2019) to 26.5× (October 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 12.8× 20.13%
FY2024 10.6× 19.98%
FY2023 8.9× 75.85%
FY2022 5.0× (32.41%)
FY2021 7.5× 3.42%
FY2020 7.2× (10.87%)
FY2019 8.1× 7.26%
FY2018 7.5× (49.49%)
FY2017 14.9× 0.82%
FY2016 14.8× (22.85%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 25.7× 20.75%
Jun 2026 21.3× 57.57%
Mar 2026 13.5× 5.63%
Dec 2025 12.8× (3.19%)
43 more quarters

Against its own ten years

Low 2.6× High 26.5×
Ten-year median 11.0×
Current reading's percentile 99

EV/Sales against peers

Company EV/Sales
BLTE Belite Bio, Inc. Sponsored ADR compare n/m
IMVT Immunovant, Inc. compare n/m
ORKA Oruka Therapeutics, Inc. compare n/m
KOD Kodiak Sciences Inc. compare n/m
PTCT PTC Therapeutics, Inc. compare 5.4×
IONS Ionis Pharmaceuticals, Inc. compare 7.0×
MIRM Mirum Pharmaceuticals, Inc. compare 9.7×
LGND Ligand Pharmaceuticals Incorporated 24.7×
CGON CG Oncology, Inc. compare 755×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LGND